Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q02078
UPID:
MEF2A_HUMAN
Alternative names:
Serum response factor-like protein 1
Alternative UPACC:
Q02078; B4DFQ7; F6XG23; O43814; Q14223; Q14224; Q59GX4; Q7Z6C9; Q96D14
Background:
Myocyte-specific enhancer factor 2A (MEF2A), also known as Serum response factor-like protein 1, plays a pivotal role in muscle-specific gene regulation, growth factor-induced gene activation, and neuronal differentiation. It binds to the MEF2 element, influencing skeletal and cardiac muscle development, neuronal survival, and synaptic differentiation through diverse signaling pathways, including p38 MAPK.
Therapeutic significance:
MEF2A's involvement in coronary artery disease, autosomal dominant, 1, underscores its potential as a therapeutic target. Understanding the role of MEF2A could open doors to potential therapeutic strategies for heart diseases and neuronal disorders.